About Steminent

Steminent Biotherapeutics Inc. is the leading stem cell clinical development company in Taipei, with subsidiaries in San Diego and Shanghai, dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes advanced, proprietary processes and know how to isolate, purify, amplify and manufacture standardized stem cell products of the highest quality for research and clinical development in multiple indications.

Steminent’s Stemchymal® allogeneic cell therapy R&D program has generated a portfolio of clinical stage therapeutic candidates for multiple diseases including: Phase II; Spinocerebellar Ataxia (PolyQ SCA), Phase I; Osteoarthritis of the Knee, and Phase I: Acute Liver Failure.

Steminent Value Propositions karen.002


 

關於仲恩生醫

幹細胞醫藥產業先驅的仲恩生醫,以推動異體間葉幹細胞治療為核心,擁有世界一流的幹細胞研發團隊與技術。獨家核心技術平台Stemchymal®,以領先全球的幹細胞分離、純化、增生技術,應用於自體及異體的脂肪間葉幹細胞治療。

仲恩生醫以最嚴謹的製藥規範與品質管理,不斷累積科學實證,並透過國內外頂尖醫學中心臨床試驗證實仲恩生醫幹細胞產品的安全與療效。除此,仲恩生醫透過與臨床醫師及國內外合作夥伴緊密的合作,持續地針對臨床未被滿足的需求,持續開發Stemchymal®優質細胞產品於急性肝衰竭及其他適應症之應用,期許未來多國的二期臨床試驗的結果,以及在其他不治和難治病症上的努力和不斷的進步,將可盡早實現幹細胞藥物在臨床應用的價值,嘉惠無藥可醫之病患。

2016年藉由台日再生醫療的策略結盟,深化台日雙方的合作關係,更促進再生醫學產業化和實用化的發展。2018年向美日兩國申請的臨床試驗二期申請案,相繼於7月14日和7月29日正式通過。一旦於日本完成異體間葉幹細胞新藥的二期臨床試驗,將依日本再生醫藥專法申請孤兒藥資格及最高7至10年暫時性藥證許可。

Advertisements